Home › FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)
 

Keywords :   


FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna's Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

2015-04-29 05:21:48| drugdiscoveryonline Home Page

Dicerna Pharmaceuticals, Inc., a leading developer of RNA interference (RNAi) therapeutics, recently announced that the U.S

Tags: type primary treatment drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 2
29.06Tropical Storm Beryl Public Advisory Number 2
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 2
29.06Tropical Storm Beryl Forecast Advisory Number 2
More »